SOURCE: BioTech Medics, Inc.

April 03, 2007 10:00 ET

BioTech Medics Announces First Quarter Insider Stock Buys

RENO, NV -- (MARKET WIRE) -- April 3, 2007 -- BioTech Medics, Inc. (PINKSHEETS: BTMD) announced today that members of the Board of Directors bought, during the first quarter of 2007, 67,008 shares of BTMD stock in the open market.

The opinion of the board is that the stock is at bargain prices and desired to show support of the Company and its shareholders.

The stock was acquired in compliance with SEC regulations. All purchases were made subsequent to the first thirty minutes and prior to the last thirty minutes of each trading day. All purchases were at the "ASK." The average share purchase price was at $.008.

BioTech owns and operates a Pain Management & Wellness Center in Dallas, Texas.

BioTech manufactures and sells Class IIIB Medical Therapeutic Lasers which have FDA 510(k) clearance. BTMD has 3 affiliated Pain Management Centers in Albuquerque, Overland Park, KS and Los Angeles. More are pending.

The Company developed and sells the SHBAN™ 3 oz. Go Anywhere Hand Sanitizer which has been clinically proven to kill the Avian Bird Flu and other viruses upon contact without harming humans, animals and the environment.

The clear superiority of SHBAN over other disinfectants is that SHBAN is longer lasting, as it leaves an invisible film on the hands. SHBAN does not evaporate within one minute after application (compared to an alcohol-based hand sanitizer). SHBAN is non-toxic (when used as directed), non-flammable, and non-bleaching and has no toxic odors. Additionally, the SHBAN 3 oz. size is convenient to carry in a purse, briefcase, backpack, waist pouch or vehicle and passes the TSA Airport carry-on liquid requirements.

SHBAN is protected under US Letters of Patent #5,514.808, #5,574,050, #5,679,711 and #5,585,391. BioTech Medics will provide SHBAN samples to government or world health officials should they desire to independently test the SHBAN solution.

Distributorships are now available. Contact the company for applications.

Safe Harbor for Forward-Looking Statements.

This press contains forward-looking statements within the meaning of The Private Securities Litigation Reform Act of 1995 (the "Act"). Such statements are subject to certain risks and uncertainties and actual results could differ materially from those expressed in any of the forward-looking statements. The FDA has not evaluated the SHBAN product. SHBAN is not for the diagnosis, treatment and/or cure of any disease. Void where prohibited.

Contact Information

  • Contact:
    BTMD Investor Relations